Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Restarting Stalled Replication Forks02:37

Restarting Stalled Replication Forks

5.8K
DNA replication is initiated at sites containing predefined DNA sequences known as origins of replication. DNA is unwound at these sites by the minichromosome maintenance (MCM) helicase and other factors such as Cdc45 and the associated GINS complex.The unwound single strands are protected by replication protein A (RPA) until DNA polymerase starts synthesizing DNA at the 5’ end of the strand in the same direction as the replication fork. To prevent the replication fork from falling apart,...
5.8K
Base Excision Repair01:54

Base Excision Repair

3.6K
3.6K
Next-generation Sequencing03:00

Next-generation Sequencing

88.7K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
88.7K
Homologous Recombination02:31

Homologous Recombination

50.5K
The basic reaction of homologous recombination (HR) involves two chromatids that contain DNA sequences sharing a significant stretch of identity. One of these sequences uses a strand from another as a template to synthesize DNA in an enzyme-catalyzed reaction. The final product is a novel amalgamation of the two substrates. To ensure an accurate recombination of sequences, HR is restricted to the S and G2 phases of the cell cycle. At these stages, the DNA has been replicated already and the...
50.5K
DNA Damage Can Stall the Cell Cycle02:37

DNA Damage Can Stall the Cell Cycle

2.6K
2.6K
Fixing Double-strand Breaks02:04

Fixing Double-strand Breaks

3.1K
3.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-World Outcomes with BCMA- and GPRC5D-Targeting Bispecific Antibodies in Plasma Cell Leukemia.

Blood advances·2026
Same author

Bridging therapy before CAR-T for multiple myeloma: a survey from the CMWP and CTIWP of the EBMT.

Bone marrow transplantation·2026
Same author

Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.

Blood cancer journal·2026
Same author

Efficacy of stem cell boost (SCB) for chimeric antigen receptor-T cell therapy (CAR-T)-related hematologic toxicity in patients with relapsed/refractory multiple myeloma (RRMM)-real world experience from the US multiple myeloma immunotherapy consortium.

Blood cancer journal·2026
Same author

The impact of extramedullary and paraskeletal plasmacytomas on treatment outcomes in multiple myeloma treated with teclistamab: U.S. Myeloma Immunotherapy Consortium real-world experience.

Blood cancer journal·2025
Same author

Daratumumab plus lenalidomide maintenance in newly diagnosed multiple myeloma after transplant: AURIGA subgroup analyses.

Blood cancer journal·2025
Same journal

Endocrinopathies and growth in a UK cohort of children with transfusion dependent thalassaemia.

British journal of haematology·2026
Same journal

Comparative effectiveness of chimeric antigen receptor (CAR) T-cell therapy versus historical controls in patients with relapse/refractory aggressive B-cell lymphoma: An indirect treatment comparison in the real-world setting.

British journal of haematology·2026
Same journal

Plasma metabolomics profile alterations in the onset and progression of paediatric immune thrombocytopenia.

British journal of haematology·2026
Same journal

Carfilzomib, lenalidomide, and dexamethasone (KRd) versus bortezomib, lenalidomide, and dexamethasone (VRd) induction prior to autologous haematopoietic stem cell transplant/transplantation in newly diagnosed multiple myeloma.

British journal of haematology·2026
Same journal

Immortal time bias limits the conclusion that post-transplant hypomethylating agent maintenance improves outcomes in myelodysplastic syndromes.

British journal of haematology·2026
Same journal

Author response to Zhang and Chen.

British journal of haematology·2026
See all related articles

Related Experiment Video

Updated: Jun 29, 2025

A Deep-sequencing-assisted, Spontaneous Suppressor Screen in the Fission Yeast Schizosaccharomyces pombe
07:55

A Deep-sequencing-assisted, Spontaneous Suppressor Screen in the Fission Yeast Schizosaccharomyces pombe

Published on: March 7, 2019

8.0K

Sequence not salvage.

Douglas W Sborov1, Gliceida Galarza Fortuna1, Patrick J Hayden2

  • 1Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah, USA.

British Journal of Haematology
|April 2, 2024
PubMed
Summary
This summary is machine-generated.

Salvage treatments after BCMA-targeted CAR-T therapy for multiple myeloma are crucial as the disease remains incurable. This study analyzes outcomes for patients needing further treatment following CAR-T therapy, highlighting the need for effective subsequent options.

Keywords:
T‐cell redirecting bispecific antibodieschimeric antigen receptor (CAR) T‐cell therapymultiple myelomaproteosome inhibitor

More Related Videos

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER
14:06

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Published on: June 23, 2012

15.2K
Optimization for Sequencing and Analysis of Degraded FFPE-RNA Samples
07:30

Optimization for Sequencing and Analysis of Degraded FFPE-RNA Samples

Published on: June 8, 2020

12.0K

Related Experiment Videos

Last Updated: Jun 29, 2025

A Deep-sequencing-assisted, Spontaneous Suppressor Screen in the Fission Yeast Schizosaccharomyces pombe
07:55

A Deep-sequencing-assisted, Spontaneous Suppressor Screen in the Fission Yeast Schizosaccharomyces pombe

Published on: March 7, 2019

8.0K
Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER
14:06

Detection of Rare Genomic Variants from Pooled Sequencing Using SPLINTER

Published on: June 23, 2012

15.2K
Optimization for Sequencing and Analysis of Degraded FFPE-RNA Samples
07:30

Optimization for Sequencing and Analysis of Degraded FFPE-RNA Samples

Published on: June 8, 2020

12.0K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • Chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) has transformed relapsed/refractory multiple myeloma (RRMM) treatment.
  • Despite initial efficacy, most patients eventually require subsequent therapies due to disease incurability.

Purpose of the Study:

  • To evaluate the outcomes of salvage treatments in patients with multiple myeloma who received BCMA-specific CAR-T therapy.
  • To identify optimal next-line therapeutic strategies following CAR-T failure in RRMM.

Main Methods:

  • Retrospective analysis of the LEGEND-2 study data.
  • Examination of patient outcomes receiving salvage therapy post-BCMA CAR-T treatment.

Main Results:

  • Most patients receiving BCMA-specific CAR-T therapy for RRMM eventually require salvage treatment.
  • The efficacy and safety of various salvage regimens following CAR-T therapy need further investigation.

Conclusions:

  • Subsequent treatment strategies are essential for managing multiple myeloma after BCMA-targeted CAR-T therapy.
  • Further research is needed to define the optimal salvage treatment pathway for patients with RRMM post-CAR-T.